Cirugía de revascularización o intervencionismo en lesiones de tronco de la arteria coronaria izquierda: un debate en curso

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al: Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961-72.

Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, Cosgrove DM. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. Ann Thorac Surg. 2004;78(6):2005-2014.

Puskas JD, Thourani VH, Kilgo P, Cooper W, Vassiliades T, Vega D, et al. Off-pump coronary artery bypass disproportionately benefits high-risk patients. Ann Thorac Surg. 2009;88:1142-7.

Edelman JJ, Yan TD, Bannon PG, Wilson MK, Vallely MP. Coronary artery bypass grafting with and without manipulation of the ascending aorta. A meta-analysis. Heart Lung Circ. 2011;20:318-24.

Smith PK. Treatment selection for coronary artery disease: the collision of a belief system with evidence. Ann Thorac Surg. 2009;87(5):1328-31.

Kappetein AP. Editorial comment: Is there enough evidence that proves clinical equipoise between stenting and coronary surgery for patients with left main coronary artery disease? Europ J Cardiothorac Surg. 2010;38:428-30.

Taggart DP. Lessons learned from the SYNTAX trial for multivessel and left main stem coronary artery disease. Curr Opin Cardiol. 2011;26(6):502-7.

Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Ståhle E. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3 year follow-up of the SYNTAX trial. Europ Heart J. 2011;32(17):2125-34.

Taggart DP. Time for coronary artery bypass grafting to make a comeback? SeminThoracCardiovasc Surg. 2011;23(1):5-7.

Serruys PW on behalf of the SYNTAX investigators: The 4-year outcomes of the SYNTAX trial in the subset of patients with left main disease. TCT 2011, Nov 7-11. San Francisco, USA. Disponible en: http://www.syntaxscore.com/index.php?option=com_rubberdoc&view=doc&id=47&format=raw

Mohr FW on behalf of the SYNTAX investigators: The 4-years outcomes of the SYNTAX trial in the subset of patients with three-vessel disease. TCT 2011, Nov 7-11. San Francisco, USA. Disponible en: http://www.syntaxscore.com/index.php?option=com_content&view=article&id=40&Itemid=75

Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, et al: Randomized trial of stent versus bypass surgery for left main coronary artery disease. N Engl J Med. 2011;364(18):1718-27.

Teirstein PS. Percutaneous revascularization is the preferred strategy for patients with significant left main coronary stenosis. Circulation. 2009;119(7):1021-33.

Stone GW. The EXCEL Trial. Design, Status and timelines. TCT 2011, Nov 7-11. San Francisco, USA. Disponible en: http://www.summitmd.com/pdf/pdf/6_Stone.pdf

Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/HFSA/ SCCT. 2012 Appropriate use for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am CollCardiol. 2012;59(9):857-81.

Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D.Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501-55.